首页> 外文期刊>Journal of Clinical Pharmacy and Therapeutics >Alveolar-capillary membrane permeability for early prediction of response of inhaled steroid on patients with chronic obstructive pulmonary disease.
【24h】

Alveolar-capillary membrane permeability for early prediction of response of inhaled steroid on patients with chronic obstructive pulmonary disease.

机译:肺泡-毛细血管膜通透性可早期预测慢性阻塞性肺疾病患者吸入类固醇的反应。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND AND OBJECTIVE: Glucocorticosteroid reversibility-testing is undertaken over a period of 3 months to identify whether patients with chronic obstructive pulmonary disease (COPD) would benefit from long-term inhaled corticosteroids. This study assessed whether alveolar-capillary membrane (a/c) permeability testing can be used as an early alternative test method for the same purpose. METHODS: Fourteen patients with severe and symptomatic moderate COPD (group S) were prescribed inhaled steroid 800 microg/day for 3 months. Before inhalation and 4 weeks after inhalation therapy, forced expiratory volume in 1 s (FEV(1)) and a/c permeability using (99m)Tc-DTPA were performed. FEV(1) was recorded again at the end of the third month. Another 10 patients with COPD of comparable severity (group B) prescribed with inhaled bronchodilators were examined and studied as controls. RESULTS: In group S, the permeability decreased in eight patients (group D) and increased in six patients (group I). No significantchange was noted in FEV(1) at the end of the first month. However, seven patients in group D showed significant improvement in FEV(1) at the end of the third month, whereas in patients in group I no significant changes were observed. In group B, no significant change in a/c permeability was observed, although the FEV(1) increased by 12-17%. CONCLUSION: With steroid inhalation, the a/c permeability at 4 weeks predicts future changes in lung functions. Long-term inhaled corticosteroids are likely to be useful if permeability decreases. This test, which needs further validation, appears to provide much earlier prediction of response than glucocorticoid reversibility testing.
机译:背景与目的:糖皮质激素可逆性测试历时3个月,旨在确定患有慢性阻塞性肺疾病(COPD)的患者是否将从长期吸入糖皮质激素中受益。这项研究评估了是否可以将肺泡-毛细血管膜(a / c)渗透性测试用作用于同一目的的早期替代测试方法。方法:十四名重度和症状性中度COPD患者(S组)被处方吸入类固醇800微克/天,持续3个月。吸入前和吸入治疗后4周,使用(99m)Tc-DTPA进行1 s的强制呼气量(FEV(1))和a / c渗透性。第三个月末再次记录了FEV(1)。检查并研究了其他10例吸入性支气管扩张剂的严重程度相当的COPD患者(B组),并作为对照进行研究。结果:在S组中,通透性降低了8名患者(D组),增加了6名患者(I组)。在第一个月末,FEV(1)中没有发现重大变化。但是,D组中有7名患者在第三个月末显示FEV(1)有显着改善,而I组中的患者没有观察到明显变化。在B组中,尽管FEV(1)增加了12-17%,但未观察到A / C渗透率的显着变化。结论:吸入类固醇后,第4周的A / C通透性可预测肺功能的未来变化。如果通透性降低,则长期吸入皮质类固醇可能会有用。与糖皮质激素可逆性测试相比,这种需要进一步验证的测试似乎提供了更早的响应预测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号